Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)

BACKGROUND: After admission to hospital, COVID-19 progresses in a substantial proportion of patients to critical disease that requires intensive care unit (ICU) admission. METHODS: In a pragmatic, non-blinded trial, 387 patients aged 40–90 years were randomised to receive treatment with SoC plus dox...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhar, Raja, Kirkpatrick, John, Gilbert, Laura, Khanna, Arjun, Modi, Mahavir Madhavdas, Chawla, Rakesh K., Dalal, Sonia, Maturu, Venkata Nagarjuna, Stern, Marcel, Keppler, Oliver T., Djukanovic, Ratko, Gadola, Stephan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870104/
https://www.ncbi.nlm.nih.gov/pubmed/36689456
http://dx.doi.org/10.1371/journal.pone.0280745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870104/
https://www.ncbi.nlm.nih.gov/pubmed/36689456
http://dx.doi.org/10.1371/journal.pone.0280745

Ejemplares similares